Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)

Gezelius, E. LU ; Bendahl, P. O. LU ; Gonçalves de Oliveira, K. LU ; Ek, L. LU ; Bergman, B. ; Sundberg, J. ; Strandberg, K. LU ; Krämer, R. and Belting, M. LU (2019) In European Journal of Cancer 118. p.82-90
Abstract

Background: Coagulation activation is a hallmark of cancer, and anticoagulants have shown tumour-inhibiting properties. However, recent trials have failed to demonstrate improved survival with low-molecular-weight heparin (LMWH) in cancer populations. This has raised the question of suboptimal adherence as a possible explanation for the lack of benefit. Still, there is no standardised method to directly monitor LMWH in patient plasma. Here, we directly determine LMWH levels in patients using the Heparin Red assay to objectively assess adherence and how this associates with the patient outcome in the RASTEN trial. Methods: RASTEN is a multicentre, randomised phase III trial investigating if the addition of LMWH to standard therapy can... (More)

Background: Coagulation activation is a hallmark of cancer, and anticoagulants have shown tumour-inhibiting properties. However, recent trials have failed to demonstrate improved survival with low-molecular-weight heparin (LMWH) in cancer populations. This has raised the question of suboptimal adherence as a possible explanation for the lack of benefit. Still, there is no standardised method to directly monitor LMWH in patient plasma. Here, we directly determine LMWH levels in patients using the Heparin Red assay to objectively assess adherence and how this associates with the patient outcome in the RASTEN trial. Methods: RASTEN is a multicentre, randomised phase III trial investigating if the addition of LMWH to standard therapy can improve survival in small-cell lung cancer. LMWH was measured in plasma (N = 258) by the Heparin Red assay and compared with the anti–factor Xa (anti-FXa) activity assay. Results: Both methods could differentiate patients in the LMWH arm from the control arm and patients receiving therapeutic LMWH owing to thrombosis. Receiver Operating Characteristic (ROC) analysis yielded adherence rates of 85% for anti-FXa and 68% for Heparin Red. No survival benefits were found in the adherent subgroup compared with the control arm (hazard ratio [HR]: 1.26; 95% confidence interval [CI]: 0.95–1.67; P = 0.105 and HR: 1.19; 95% CI: 0.89–1.60; P = 0.248 for anti-FXa and Heparin Red, respectively). Heparin Red could define patients with high probability of adherence to LMWH treatment, which warrants prospective studies for further validation. Our finding that the LMWH-adherent subpopulation did not show improved survival excludes that the negative outcome of RASTEN was due to poor adherence.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Anticoagulant therapy adherence, Heparin assays, Lung cancer
in
European Journal of Cancer
volume
118
pages
9 pages
publisher
Elsevier
external identifiers
  • scopus:85069044306
  • pmid:31326730
ISSN
0959-8049
DOI
10.1016/j.ejca.2019.06.015
language
English
LU publication?
yes
id
3cef5a7e-a355-4b4e-831f-50f337d04fb6
date added to LUP
2019-07-26 09:24:44
date last changed
2024-02-15 18:12:02
@article{3cef5a7e-a355-4b4e-831f-50f337d04fb6,
  abstract     = {{<p>Background: Coagulation activation is a hallmark of cancer, and anticoagulants have shown tumour-inhibiting properties. However, recent trials have failed to demonstrate improved survival with low-molecular-weight heparin (LMWH) in cancer populations. This has raised the question of suboptimal adherence as a possible explanation for the lack of benefit. Still, there is no standardised method to directly monitor LMWH in patient plasma. Here, we directly determine LMWH levels in patients using the Heparin Red assay to objectively assess adherence and how this associates with the patient outcome in the RASTEN trial. Methods: RASTEN is a multicentre, randomised phase III trial investigating if the addition of LMWH to standard therapy can improve survival in small-cell lung cancer. LMWH was measured in plasma (N = 258) by the Heparin Red assay and compared with the anti–factor Xa (anti-FXa) activity assay. Results: Both methods could differentiate patients in the LMWH arm from the control arm and patients receiving therapeutic LMWH owing to thrombosis. Receiver Operating Characteristic (ROC) analysis yielded adherence rates of 85% for anti-FXa and 68% for Heparin Red. No survival benefits were found in the adherent subgroup compared with the control arm (hazard ratio [HR]: 1.26; 95% confidence interval [CI]: 0.95–1.67; P = 0.105 and HR: 1.19; 95% CI: 0.89–1.60; P = 0.248 for anti-FXa and Heparin Red, respectively). Heparin Red could define patients with high probability of adherence to LMWH treatment, which warrants prospective studies for further validation. Our finding that the LMWH-adherent subpopulation did not show improved survival excludes that the negative outcome of RASTEN was due to poor adherence.</p>}},
  author       = {{Gezelius, E. and Bendahl, P. O. and Gonçalves de Oliveira, K. and Ek, L. and Bergman, B. and Sundberg, J. and Strandberg, K. and Krämer, R. and Belting, M.}},
  issn         = {{0959-8049}},
  keywords     = {{Anticoagulant therapy adherence; Heparin assays; Lung cancer}},
  language     = {{eng}},
  pages        = {{82--90}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer}},
  title        = {{Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)}},
  url          = {{http://dx.doi.org/10.1016/j.ejca.2019.06.015}},
  doi          = {{10.1016/j.ejca.2019.06.015}},
  volume       = {{118}},
  year         = {{2019}},
}